I-Mab reported its second quarter 2025 financial results, highlighting a pro-forma cash balance of approximately $226.8 million as of June 30, 2025. This figure includes the net proceeds from the August 2025 underwritten offering, significantly strengthening the company's financial position.
The company announced that its cash runway has been extended into the fourth quarter of 2028, providing substantial financial stability to advance its pipeline through critical clinical milestones. This extended runway is crucial for funding ongoing and planned clinical trials.
I-Mab reiterated the positive givastomig Phase 1b dose escalation data, which showed an 83% objective response rate at doses selected for the ongoing expansion study, as presented at ESMO GI 2025. Topline data from the planned dose expansion study of givastomig are expected in the first quarter of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.